6.300SEK-1.56%Mkt Cap: 88.50M SEKP/E: —Last update: 2026-06-01
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers Bup…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap88.50M SEK
Enterprise Value99.53M SEK
Revenue (TTM)2.78M SEK
Gross Profit2.78M SEK
Net Income (TTM)-15.94M SEK
Revenue/Share0.2300 SEK
Last Price6.300 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-32.00
PEG—
EV/EBITDA—
EV/Revenue35.75
P/S32.29
P/B9.55
EPS (TTM)-1.90
EPS (Forward)-0.20
52W Range
4.51531% of range10.28
52W High10.28 SEK
52W Low4.515 SEK
Profitability
Gross Margin100.00%
Oper. Margin-974800.00%
EBITDA Margin0.00%
Profit Margin-598.35%
ROE-188.04%
ROA-65.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.06M SEK
CapEx (TTM)—
FCF Margin-254.47%
FCF Yield-8.00%
Net Debt3.79M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.88
Current Ratio1.01
Quick Ratio0.74
Book Value/Sh0.6700 SEK
Cash/Share0.2940 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)11.50 SEK
Target Range11.50 SEK – 11.50 SEK
# Analysts1
Ownership
Shares Out.14.05M
Float4.43M
Insiders45.10%
Institutions10.58%
Technical
SMA 506.158 (+2.3%)
SMA 2006.011 (+4.8%)
Beta1.33
S&P 52W Chg27.70%
Avg Vol (30d)50.13K
Avg Vol (10d)95.95K
Technical Indicators
RSI (14)47.7
MACD0.1994
MACD Signal0.2599
MACD Hist.-0.0606
BB Upper7.576 SEK
BB Middle6.626 SEK
BB Lower5.676 SEK
BB Width28.68%
ATR (14)0.7038 SEK
Vol Ratio (20d)0.93x